Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Time Points, Dynamics and Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with NPM1 mutation: A Study on 428 Patients

Torsten Haferlach, MD, Claudia Haferlach, MD, Wenke Worseg, Karolína Perglerová, Wolfgang Kern, MD, Manja Meggendorfer, PhD

Blood (2016) 128 (22): 1710.

https://doi.org/10.1182/blood.V128.22.1710.1710

Published: 2016

Journal Articles

CSF3R Mutations Are Predominantly Subclonal Events in Intermediate Risk Karyotype AML and Prevalently Occur with CEBPA Mutations

Annette Fasan, PhD, Claudia Haferlach, MD, Karolína Perglerová, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2016) 128 (22): 1658.

https://doi.org/10.1182/blood.V128.22.1658.1658

Published: 2016

Journal Articles

SF3B1 Mutations in AML, MDS and MDS/MPN-RS-T Are Accompanied By Different Other Gene Mutations: Impact for Targeted Treatment Studies

Manja Meggendorfer, PhD, Sabine Jeromin, PhD, Karolína Perglerová, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2016) 128 (22): 1976.

https://doi.org/10.1182/blood.V128.22.1976.1976

Published: 2016

Journal Articles

A Comprehensive Panel of Molecular Mutations Notably Improves a Cytogenetic Prognostication System in Routine AML Diagnostics

Claudia Haferlach, MD, Manja Meggendorfer, PhD, Annette Fasan, PhD, Karolina Perglerová, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2016) 128 (22): 286.

https://doi.org/10.1182/blood.V128.22.286.286

Published: 2016

Journal Articles

The Number of RUNX1 Mutations and the Presence of One Intact RUNX1 Allele Influence Cytogenetic Abnormalities, Additional Molecular Mutations and Prognosis in RUNX1 Mutated AML

Anna Stengel, PhD, Wolfgang Kern, MD, Manja Meggendorfer, PhD, Karolina Perglerová, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2016) 128 (22): 284.

https://doi.org/10.1182/blood.V128.22.284.284

Published: 2016

Journal Articles

Landscape of Secondary Genetic Lesions in Acute Myeloid Leukemia with Inv(16)/ CBFB-MYH11

Annette Fasan, PhD, Claudia Haferlach, MD, Karolína Perglerová, Sonja Schindela, Susanne Schnittger, PhD, Wolfgang Kern, MD, Torsten Haferlach

Blood (2015) 126 (23): 801.

https://doi.org/10.1182/blood.V126.23.801.801

Published: 2015

Journal Articles

Abnormalities Detected By Array CGH and Fluorescence in Situ Hybridization in AML with Normal Karyotype Lacking Mutations in NPM1 , CEBPA , RUNX1 and MLL Partial Tandem Duplications Are Associated with Unfavorable Outcome

Claudia Haferlach, MD, Kathleen Zieschang, Susanne Schnittger, PhD, Tamara Alpermann, Melanie Zenger, Karolína Perglerová, Wolfgang Kern, MD, Torsten Haferlach

Blood (2015) 126 (23): 1371.

https://doi.org/10.1182/blood.V126.23.1371.1371

Published: 2015

Journal Articles

BAALC Expression Is a Feasible Marker for Risk Stratification and Detection of Minimal Residual Disease in Cytogenetically Normal Acute Myeloid Leukemia

Simone Weber, Tamara Alpermann, Karolína Perglerová, Susanne Schnittger, PhD, Torsten Haferlach, Claudia Haferlach, MD, Wolfgang Kern, MD

Blood (2015) 126 (23): 1373.

https://doi.org/10.1182/blood.V126.23.1373.1373

Published: 2015

Journal Articles

Does Age of Patients Influence the Composition of Gene Mutations in Myeloid Neoplasms?

Manja Meggendorfer, PhD, Wolfgang Kern, MD, Karolína Perglerová, Susanne Schnittger, PhD, Claudia Haferlach, MD, Torsten Haferlach

Blood (2015) 126 (23): 3821.

https://doi.org/10.1182/blood.V126.23.3821.3821

Published: 2015

Journal Articles

Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity?

Simone Weber, Manja Meggendorfer, PhD, Niroshan Nadarajah, M.Sc., Karolína Perglerová, Susanne Schnittger, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach

Blood (2015) 126 (23): 3846.

https://doi.org/10.1182/blood.V126.23.3846.3846

Published: 2015

Journal Articles

Higher Percentages of Ring Sideroblasts and SF3B1 Mutations in Patients with AML Correlate with Mutations in TP53 and Adverse Cytogenetics, but Have No Independent Impact on Outcome

Pedro Martin-Cabrera, MD, Sabine Jeromin, PhD, Tamara Alpermann, Karolína Perglerová, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach

Blood (2015) 126 (23): 3847.

https://doi.org/10.1182/blood.V126.23.3847.3847

Published: 2015

Journal Articles

AML with RUNX1 Mutations and Loss of RUNX1 Wild-Type - a Distinct Subset?

Claudia Haferlach, MD, Niroshan Nadarajah, M.Sc., Annette Fasan, PhD, Karolína Perglerová, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach

Blood (2015) 126 (23): 2578.

https://doi.org/10.1182/blood.V126.23.2578.2578

Published: 2015

Journal Articles

Specific Patterns of Molecular Mutations Determine the Morphologic Differentiation Stages in Acute Myeloid Leukemia (AML)

Dominic Rose, PhD, Torsten Haferlach, MD, Susanne Schnittger, PhD, Karolina Perglerová, Wolfgang Kern, MD, Claudia Haferlach, MD

Blood (2014) 124 (21): 2388.

https://doi.org/10.1182/blood.V124.21.2388.2388

Published: 2014

Journal Articles

Complexity of CEBPA Mutated Acute Myeloid Leukemia

Annette Fasan, PhD, Claudia Haferlach, MD, Karolina Perglerová, Wolfgang Kern, MD, Torsten Haferlach, MD, Susanne Schnittger, PhD

Blood (2014) 124 (21): 2348.

https://doi.org/10.1182/blood.V124.21.2348.2348

Published: 2014

Journal Articles

Cytogenetic and Molecular Genetic Shifts in 27 Genes Investigated By NGS Depict Specific Routes from MDS to s-AML in 38 Patients with Paired Samples

Andreia De Albuquerque, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Karolina Perglerová, Tamara Alpermann, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach

Blood (2014) 124 (21): 2378.

https://doi.org/10.1182/blood.V124.21.2378.2378

Published: 2014

Journal Articles

In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML

Susanne Schnittger, PhD, Claudia Haferlach, MD, Niroshan Nadarajah, M.Sc., Tamara Alpermann, Manja Meggendorfer, PhD, Karolina Perglerová, Wolfgang Kern, MD, Torsten Haferlach

Blood (2014) 124 (21): 700.

https://doi.org/10.1182/blood.V124.21.700.700

Published: 2014

Journal Articles

A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker

Anna Stengel, PhD, Wolfgang Kern, MD, Melanie Zenger, Karolina Perglerová, Susanne Schnittger, PhD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2014) 124 (21): 1639.

https://doi.org/10.1182/blood.V124.21.1639.1639

Published: 2014

Journal Articles

Genetic Patterns of Relapsed AML Differ Significantly from First Manifestation and Are Dependent on Cytogenetic Risk Groups at Diagnosis: Results in 175 Patients with Paired Samples

Manja Meggendorfer, PhD, Tamara Alpermann, Karolina Perglerová, Wolfgang Kern, MD, Susanne Schnittger, PhD, Claudia Haferlach, MD, Torsten Haferlach

Blood (2014) 124 (21): 1029.

https://doi.org/10.1182/blood.V124.21.1029.1029

Published: 2014

Journal Articles

DNMT3A is a Powerful Follow-up Marker in NPM1 mutated AML

Susanne Schnittger, PhD, Claudia Haferlach, MD, Tamara Alpermann, Niroshan Nadarajah, M.Sc., Manja Meggendorfer, PhD, Karolina Perglerová, Wolfgang Kern, MD, Torsten Haferlach

Blood (2014) 124 (21): 122.

https://doi.org/10.1182/blood.V124.21.122.122

Published: 2014

NARROW

Time Points, Dynamics and Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with NPM1 mutation: A Study on 428 Patients

CSF3R Mutations Are Predominantly Subclonal Events in Intermediate Risk Karyotype AML and Prevalently Occur with CEBPA Mutations

SF3B1 Mutations in AML, MDS and MDS/MPN-RS-T Are Accompanied By Different Other Gene Mutations: Impact for Targeted Treatment Studies

A Comprehensive Panel of Molecular Mutations Notably Improves a Cytogenetic Prognostication System in Routine AML Diagnostics

The Number of RUNX1 Mutations and the Presence of One Intact RUNX1 Allele Influence Cytogenetic Abnormalities, Additional Molecular Mutations and Prognosis in RUNX1 Mutated AML

Landscape of Secondary Genetic Lesions in Acute Myeloid Leukemia with Inv(16)/ CBFB-MYH11

Abnormalities Detected By Array CGH and Fluorescence in Situ Hybridization in AML with Normal Karyotype Lacking Mutations in NPM1 , CEBPA , RUNX1 and MLL Partial Tandem Duplications Are Associated with Unfavorable Outcome

BAALC Expression Is a Feasible Marker for Risk Stratification and Detection of Minimal Residual Disease in Cytogenetically Normal Acute Myeloid Leukemia

Does Age of Patients Influence the Composition of Gene Mutations in Myeloid Neoplasms?

Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity?

Higher Percentages of Ring Sideroblasts and SF3B1 Mutations in Patients with AML Correlate with Mutations in TP53 and Adverse Cytogenetics, but Have No Independent Impact on Outcome

AML with RUNX1 Mutations and Loss of RUNX1 Wild-Type - a Distinct Subset?

Specific Patterns of Molecular Mutations Determine the Morphologic Differentiation Stages in Acute Myeloid Leukemia (AML)

Complexity of CEBPA Mutated Acute Myeloid Leukemia

Cytogenetic and Molecular Genetic Shifts in 27 Genes Investigated By NGS Depict Specific Routes from MDS to s-AML in 38 Patients with Paired Samples

In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML

A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker

Genetic Patterns of Relapsed AML Differ Significantly from First Manifestation and Are Dependent on Cytogenetic Risk Groups at Diagnosis: Results in 175 Patients with Paired Samples

DNMT3A is a Powerful Follow-up Marker in NPM1 mutated AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only